Susan L. Kelley, M.D., has been developing drugs in oncology and immunology for over 30 years. Dr. Kelley received her M.D. from Duke University School of Medicine. She was a Fellow in Medical Oncology at Dana-Farber Cancer Institute, Harvard Medical School, and was a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine.

Dr. Kelley joined the pharmaceutical industry and worked with Bristol-Myers Squibb in Oncology and Immunology drug development from 1987 to 2001. From 2001 to 2008, Dr. Kelley worked  with Bayer Healthcare Pharmaceuticals as Vice President, Global Clinical Development and Therapeutic Area Head – Oncology. She led the Bayer team responsible for the development and worldwide regulatory approval of Nexavar (sorafenib) in kidney cancer and liver cancer and was also responsible for clinical development of the early pipeline drug candidates.

From 2008 to 2011, she was Chief Medical Officer of the Multiple Myeloma Research Consortium and its sister organization, the Multiple Myeloma Research Foundation, where her leadership responsibilities included the strategic design and management of clinical trials conducted by a consortium of leading myeloma clinical research centers in North America.

She is now an independent consultant to the pharmaceutical and biotechnology industries in the field of oncology drug development and serves as an Independent Director on the Boards of Directors of publicly-traded biotechnology companies. She served as a member of the Board of Directors of ArQule, Inc from 2011 until its acquisition by Merck & Co. in January 2020 and as a Director at Alchemia, Ltd in Australia from 2013-2015. Dr. Kelley was also a Director at Immune Design, Inc from 2016 until its acquisition by Merck & Co in 2019. She is currently a Director at Daré Bioscience (formerly Cerulean Pharma), VBL Therapeutics and Deciphera Pharmaceuticals.